In a report issued on June 30, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL). The company’s shares closed last Thursday at $23.56.
According to TipRanks.com, Hsieh is a 5-star analyst with an average return of 19.5% and a 58.6% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Viking Therapeutics, and Seattle Genetics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $29.09 average price target, which is a 24.2% upside from current levels. In a report issued on June 30, Piper Sandler also maintained a Buy rating on the stock with a $30.00 price target.
See today’s analyst top recommended stocks >>
Exelixis’ market cap is currently $7.21B and has a P/E ratio of 25.50. The company has a Price to Book ratio of 4.32.
Based on the recent corporate insider activity of 137 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Most recently, in May 2020, Vincent Marchesi, a Director at EXEL sold 40,000 shares for a total of $985,600.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
